# SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

> **NCT06361979** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Huihua Xiong** · enrollment: 30 (estimated)

## Conditions studied

- Breasr Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06361979
- **Lead sponsor:** Huihua Xiong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05
- **Primary completion:** 2025-05
- **Final completion:** 2026-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06361979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06361979, "SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06361979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*